I’ve known UK diagnostics company Lab-21 for some years now. My previous company Opaldia and Lab-21 effectively ‘grew up’ together. 

Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen’s new drug for advanced bowel cancer Vectibix® (panitumumab).
It is the first time that the European Commission (EU) has licensed a bowel cancer product with the stipulation that a predictive test should be carried out.  This is the start of companion diagnostics. The …read more